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Summary
Objective: To evaluate the efﬁcacy and tolerability of aceclofenac, 200 mg/day, and paracetamol, 3000 mg/day, in the treatment of
osteoarthritis (OA) of the knee.
Methods: This was a double-blind, parallel-group, multicentre clinical trial involving patients with symptomatic OA of the knee, conducted in
Spain. Patients were randomly allocated to aceclofenac 100 mg twice daily (n¼ 82) or paracetamol 1000 mg three times daily (n¼ 86).
Patients were assessed at baseline and 6 weeks. Primary efﬁcacy measures were severity of pain (visual analogue scale, VAS), Lequesne
OA knee index, and patient’s and physician’s global assessment of disease activity. Severity of knee pain at rest or walking, stiffness, knee
swelling and tenderness, and assessment of health-related quality of life (Health Assessment Questionnaire, Western Ontario and McMaster
Universities Osteoarthritis Index, and Short Form 36) were included as secondary endpoints.
Results: Both treatment groups showed signiﬁcant improvement compared with their baseline values in the four primary endpoints. Mean
between-treatment differences favoured aceclofenac over paracetamol on pain (VAS, 7.64 mm [95% conﬁdence interval (CI),
0.44e14.85 mm]), Lequesne OA index (1.41 [95% CI, 0.45e2.36]), and patient’s (0.33 [95% CI, 0.06e0.61]) and physician’s (0.23 [95%
CI, 0.01e0.47]) global assessments. Adverse events were similar for both drugs (paracetamol, 29% patients vs aceclofenac, 32%;
P¼ 0.71). Four patients withdrew in each group due to adverse events. Patients tended to prefer aceclofenac to paracetamol (P¼ 0.001),
and more treated with paracetamol withdrew from the study due to lack of efﬁcacy (n¼ 8 vs n¼ 1, P¼ 0.035, for paracetamol and aceclofe-
nac, respectively).
Conclusion: At 6 weeks, patients with symptomatic OA of the knee showed a greater improvement in pain and functional capacity with ace-
clofenac than paracetamol with no difference in tolerability.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a primary cause of morbidity associ-
ated with rheumatic diseases. In the near future, the ageing
population and the decline in physical function when hips
and knees are affected by OA will increase the impact
of this condition on health care utilization. In Spain, the
Estudio Epidemiolo´gico de la Sociedad Espan˜ola de
Reumatologı´a (EPISER) Study indicated that up to 29%
of people >60 years had symptomatic OA of the knee1.
Paracetamol has been recommended as the initial ther-
apy for the treatment of pain in knee OA, primarily due to0
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drugs (NSAIDs) are reserved for those patients who do not
improve, who have more severe symptoms, or who have
signs of joint inﬂammation3e5. The published evidence for
the efﬁcacy of paracetamol in OA compared with placebo
or NSAIDs is quite limited. Table I shows the most relevant
trials retrieved after a search strategy including Medline and
Cochrane databases with the following descriptors: os-
teoarthritis, knee/therapy [MeSH]; anti-inﬂammatory agents,
non-steroidal/therapeutic use [MeSH]; paracetamol; acet-
aminophen; limited to clinical trials, meta-analyses, ran-
domized controlled trials, and reviews. Publications in
non-European languages were excluded, and a manual
search from retrieved studies was done.
Findings were reported from a parallel-group trial, in
which paracetamol (4000 mg/day), diclofenac (150 mg/
day), and placebo were assessed for pain relief in knee
OA6. In this trial, paracetamol was judged no more efﬁca-
cious than placebo at 2 (P¼ 0.92) and 12 (P¼ 0.19) weeks.
Diclofenac provided improved pain control from baseline at
both 2 and 12 weeks using the WOMAC OA index; how-
ever, at 12 weeks, diclofenac was no longer superior to par-
acetamol or placebo (P¼ 0.25)6.
Paracetamol was also compared to placebo in two simul-
taneous, double-blind, double-dummy, two-period cross-
over trials involving patients with OA of the knee or hip
(PACES-a and PACES-b)7. Despite their identical design,
PACEs-a and PACES-b showed some differences in their
results. Paracetamol (4000 mg/day) was more efﬁcacious
than placebo, generally P< 0.05, in PACES-a but not in
PACES-b (P> 0.05). Celecoxib, 200 mg/day, was more
efﬁcacious than paracetamol in both periods in both studies.
A pooled estimate of these trials found that paracetamol
was more effective than placebo for pain relief in OA8,9.
Although a third trial was not able to detect any difference
between paracetamol and placebo in the treatment of OA
knee ﬂares10, its ﬁndings have been questioned9.
The remaining published studies assessing the efﬁcacy
of paracetamol in OA have involved active comparators,
i.e., NSAIDs4,5. Bradley et al.11 compared paracetamol
(4000 mg/day) with analgesic and anti-inﬂammatory doses
of ibuprofen (1200 mg and 2400 mg/day, respectively). Al-
though the authors concluded that the efﬁcacy of paraceta-
mol was similar to that of ibuprofen, independent of the
dosage, only patients treated with ibuprofen had a statisti-
cally signiﬁcant improvement in both walking pain and rest
pain, with statistically greater improvement in rest pain in
the ibuprofen group compared with paracetamol. In two
post hoc analyses of this study, the authors found that nei-
ther the intensity of pain nor signs of joint inﬂammation were
able to predict a greater response to ibuprofen than
paracetamol12,13.
Williams et al.14 compared paracetamol (2600 mg daily)
with naproxen (750 mg daily) in a 2-year, randomized,double-blind trial. Between-group comparisons showed
naproxen to be superior to paracetamol for only pain at
rest. The authors concluded that the efﬁcacy of paracetamol
and naproxen was similar, despite an appearance of a better
response for naproxen. A meta-analysis4, including both tri-
als11,14, suggested that NSAIDs were slightly more effective
than simple analgesia, although paracetamol should be the
ﬁrst treatment for OA pain due to its better cost effective
proﬁle.
More recently, Pincus et al.15 compared diclofenac plus
misoprostol (150 mg and 400 mg/day, respectively) with par-
acetamol (4000 mg/day) in a double-blind, two-period,
crossover trial in patients with hip or knee OA. After 6
weeks, diclofenac/misoprostol provided signiﬁcantly more
improvement in both primary outcomes (pain VAS and
WOMAC), compared to paracetamol, although paracetamol
was associated with fewer adverse events. Accordingly,
more patients, who took both drugs in a random order, rated
diclofenac/misoprostol as ‘‘better’’ or ‘‘much better’’ than
paracetamol15.
Finally, Geba et al.16, compared the efﬁcacy of rofecoxib
(12.5 and 25 mg/day), celecoxib (200 mg/day), and parace-
tamol (4000 mg/day) in a 6-week, double-blind clinical trial.
Rofecoxib, at 25 mg daily, provided greater therapeutic
beneﬁts than paracetamol in all prespeciﬁed endpoints,
whereas rofecoxib at the lower dose and celecoxib were
not proven to have any advantage over paracetamol. Two
meta-analyses including data from COX-2 inhibitors
showed that NSAIDs were consistently superior to parace-
tamol in pain relief across the evaluated studies with a trend
for improved safety favouring paracetamol8,17.
The debate about when to use paracetamol and when to
use NSAIDs in patients with OA has been ongoing for at
least 20 years18. Prolonged use of non-selective NSAIDs
can lead to signiﬁcant mortality and morbidity from gastroin-
testinal (GI) bleeding, ulceration, and perforation, whereas
paracetamol has a very low incidence of GI side-effects19.
By contrast, COX-2 selective NSAIDs appear to have an
incidence of GI ulceration comparable to placebo, and a
reduced risk of complicated and symptomatic ulcers com-
pared to conventional NSAIDs19. The advantages leading
to suggest these more selective NSAIDs as a ﬁrst-line treat-
ment for OA of the knee have been offset by its increased
risk of cardiovascular events including heart attacks and
strokes20. Additional concerns have been raised about the
cardiovascular safety related to the more classical non-
selective NSAIDs21,22.
Aceclofenac is a phenylacetic acid derivative structurally
related to diclofenac that has shown a higher therapeutic
index than other NSAIDs with similar analgesic and anti-
inﬂammatory activity in animal models23. Aceclofenac
(100 mg) exhibits a sustained block of COX-2 in vivo,
but only a minor inhibition of COX-1, compared with
75 mg diclofenac24. Controlled clinical trials haveTable I
Controlled clinical trials comparing paracetamol and NSAIDs in knee OA
Authors Joint Design Treatment arms, n (mg/day) Trial duration
Bradley, 199111 Knee Parallel Paracetamol; Ibuprofen; Ibuprofen; 61(4000); 62(1200); 62(2400) 4 weeks
Williams, 199314 Knee Parallel Paracetamol; Naproxen; 88(2600); 90(750) 2 years
Pincus, 200115 Knee (78%), hip (22%) Crossover Paracetamol; Diclofenac; 180(4000 mg); 180(150 mg) 6 weeks
Geba, 200216 Knee Parallel Paracetamol; Celecoxib; Rofecoxib; Rofecoxib; 94(4000);
97(200); 96(12.5); 95(25)
6 weeks
Case, 20036 Knee Parallel Paracetamol; Diclofenac; Placebo; 29(4000); 25(150); 28(e) 12 weeks
Pincus, 20047
(PACES)
Knee (85%), hip (15%) Crossover Paracetamol; Celecoxib; Placebo; 114(4000); 121(200); 115(e) 6 weeks
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ated in patients with OA, rheumatoid arthritis, and anky-
losing spondylitis25e29. Aceclofenac is one of the most
widely used NSAIDs in Spain. Due to the paucity of
data about paracetamol in OA of the knee, and of direct
comparative data vs aceclofenac in particular, we as-
sessed the efﬁcacy of aceclofenac (200 mg/day) com-
pared to paracetamol (3000 mg/day) in the treatment of
patients with symptomatic knee OA in a 6-week, multi-
centre, parallel, double-blind, randomized clinical trial.
Patients and methods
PATIENT POPULATION
Outpatients, aged 30e75 years, with primary knee OA
(patients with radiological chondrocalcinosis were allowed),
degrees II or III according to KellgreneLawrence classiﬁca-
tion30, history of knee pain for at least 3 months in the last
year, current knee pain 30 mm on a visual analogue
scale, and American College of Rheumatology (ACR) func-
tional classes IeIII31, were recruited from six Spanish rheu-
matology units. Patients were excluded for the following
reasons: if they had any other kind of arthritis or connective
tissue disease; knee trauma within the last three months;
previous open intervention in the knee or being on a waiting
list for joint replacement surgery; pregnancy or lactation;
renal (creatinine> 1.5 mg/dl) or hepatic disease; concomi-
tant serious medical condition or expected survival time
less than 2 years; myocardial infarction or stroke in the
last 4 months; history of peptic ulceration in the last two
years or perforation, gastrectomy or upper GI bleeding;
hypersensitivity to paracetamol or aceclofenac; use of cor-
ticosteroid in the past 3 months; concomitant use of oral
anticoagulants, aspirin, corticosteroids, lithium, phenytoin,
thyroxine or probenecid. Female patients with childbearing
potential who were not practising adequate contraceptive
measures and patients enrolled in any other clinical trial
within the previous 3 months or who were applying for dis-
ability for any reason were also excluded. This clinical trial
was approved by the ethics committee of each centre. All
patients gave their informed consent in written before
entering the study.
STUDY DESIGN
This study was a 6-week, randomized, double-blind,
double-dummy, parallel-group, multicentre clinical trial.
After the initial screening visit for medical history and exam-
ination, eligible patients taking NSAIDs entered a washout
period of one week. During this period, only paracetamol
was allowed to be taken until 48 h before the baseline visit.
Patients had to fulﬁl inclusion criteria at baseline visit.
TREATMENT ASSIGNMENT AND CONCEALMENT
Patients were randomly allocated to either aceclofenac or
placebo treatments, in balanced blocks of four within each
centre, by computer generated random numbers, which
were concealed in opaque sealed envelopes. Active and
placebo tablets, as well as active and placebo sachets,
were identical in appearance to preserve the double-
dummy design. Medication was packaged in sachets con-
taining 1000 mg of paracetamol and tablets of 100 mg of
aceclofenac presented in blister packs. Patients in the ace-
clofenac group received one 100 mg tablet and one placebosachet in the morning, one placebo sachet at noon, and one
100 mg tablet with one placebo sachet at night. Those in the
paracetamol group received one sachet of 1000 mg with
one tablet of placebo in the morning, one sachet of
1000 mg at noon, and one sachet of 1000 mg with one
tablet of placebo at night.
Patients remained at the same dose during the 6 weeks
of the trial. Study medications were taken after meals.
Tablet and sachet counts were performed to account for
compliance. During the trial, antacid, anti-H2 or proton
pump inhibitors were allowed. Concurrent corticosteroid in-
jection was not permitted. Patients were encouraged to
keep the same level of physical activity and physical
therapy.
ASSESSMENTS
The trial included only two visits: baseline and 6 weeks
(termination). The following clinical assessments were
made at both visits; pain and stiffness assessments were
based on the previous 48 h: (1) severity of pain on
a 100 mm horizontal visual analogue scale (VAS, 0¼ none,
100¼ extreme); (2) pain at rest; (3) pain on initiation of
walking; and (4) pain on walking, each on a 5-point Likert
scale (0¼ none, 1¼mild, 2¼moderate, 3¼ severe,
4¼ extreme); (5) duration of morning stiffness from arising
until improving (minutes); (6) severity of inactivity stiffness
later in the day, for example after sitting or lying, on a 5 point
Likert scale (0¼ none, 1¼mild, 2¼moderate, 3¼ severe,
4¼ extreme); (7) knee swelling (0¼ none, 1¼ swelling
just palpable, 2¼ swelling palpable and visible, 3¼ swelling
distorts the normal joint contours); (8) knee tenderness with
a modiﬁed Doyle articular index32 (0¼ no tenderness,
1¼ pain, 2¼ pain and winces, 3¼ pain, winces, and with-
drawn); (9) patient’s global assessment of disease activity
(1¼ very good, 2¼ good, 3¼ fair, 4¼ poor, 5¼ very
poor); (10) physician’s global assessment of disease activ-
ity (1¼ asymptomatic, 2¼ slight, 3¼moderate, 4¼ severe,
5¼ very severe); (11) the Lequesne OA knee index33,
(0e24, asymptomatic e severe), a composite index which
essentially evaluates pain, stiffness, and function; and
(12) health-related quality of life measured with the aid of
three widely used questionnaires: Health Assessment
Questionnaire, Western Ontario and McMaster Universities
Osteoarthritis Index, and Short Form 36 (HAQ, WOMAC,
and SF-36) (see below for more details). Primary efﬁcacy
measures were: (1) severity of pain (VAS), (2) Lequesne
OA knee index, (3) patient’s global assessment of disease
activity, and (4) physician’s global assessment of disease
activity. All other variables were considered as secondary.
At baseline visit, and after the clinical assessment was
made, the investigator determined the most severely
affected knee for each patient, which was used for the efﬁ-
cacy analysis. At the end of the trial a physician’s and
patient’s global assessment of the clinical efﬁcacy of the
treatment compared to baseline was ascertained on a
7-point Likert scale (1¼ a lot better, 2¼ fairly better,
3¼ little better, 4¼ same, 5¼ little worse, 6¼ fairly worse,
7¼much worse). All disease activity measurements in
each patient were performed by the same investigator.
MEASURES OF HEALTH-RELATED QUALITY OF LIFE
Two speciﬁc and one generic questionnaire were used to
characterize the perceived impact of knee OA on patients’
health-related quality of life.
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questionnaire, which includes 20 items on daily living activ-
ities related to physical function34. The ﬁnal score is the
sum of the worst score from each category, divided by the
number of categories explored (usually 8). The previously
validated Spanish version of the HAQ disability index was
used for this study35. Scores pertaining to lower-extremity
function were analysed as a subset of the HAQ11.
TheWOMAC Universities Osteoarthritis Index is a speciﬁc
questionnaire for OA of the knee and hip which contains 24
items concerning pain, stiffness, and physical function36.
The Likert version of this questionnaire (WOMAC LK 3.0),
transculturally adapted to Spanish people, was used in this
study37. Each item is scored from 0 (none) to 4 (extreme).
The totalWOMACscorewas calculated by themost common
approach, the simple summation of the 24 component item
scores. Although the validity of this overall score has not
been completely established, this score has been reported
in several trials6,15 and we included it here among the sec-
ondary efﬁcacy variables.
The SF-36 is a generic health status questionnaire that
comprises 36 items which are summed and transformed
according to standard algorithms in order to obtain a ﬁnal
score from 0 (poor health) to 100 (good health)38,39.
SAFETY AND TOLERABILITY
Safety and tolerability were based on history, physical
exam, laboratory testing, at baseline and end of trial, and re-
porting of adverse events. Number of patients with adverse
events, and number of patients withdrawn due to adverse
events were the primary outcomes of tolerability. Type
and severity of adverse events were also evaluated. Ad-
verse events were rated by the patients as mild, moderate,
or severe. The investigators determined whether adverse
events were possibly related, related or not related to the
study medication.
STATISTICAL ANALYSIS
We calculated the sample size required to detect a mean
difference of 12 mm for severity of pain on VAS between
patients treated with aceclofenac and paracetamol, with
an estimated standard deviation of 2240, an alpha level of
0.05 (two-tailed), and a power of 90%. With these assump-
tions and estimating a dropout rate of 15%, we obtained a ﬁ-
nal sample size of at least 80 patients per treatment group.
The following clinical assessments were considered, a
priori, as primary efﬁcacy measures: (1) severity of pain
(VAS), (2) Lequesne OA knee index, (3) patient’s global as-
sessment of disease activity, and (4) physician’s global as-
sessment of disease activity. Efﬁcacy was assessed with an
intention-to-treat analysis; the safety population included all
patients who were randomized and who received at least
one dose of study medication. Thus, the same population
was used for both efﬁcacy and safety analyses. For those
patients who withdrew for any reason before the end of
the trial, the baseline observations were carried forward.
Categorical data were compared by the chi-square,
ManteleHaenszel, or Fisher’s exact test. Continuous vari-
ables were evaluated using the unpaired t test, or, for
within-group comparisons (i.e., ﬁnal vs baseline values),
the paired t test. Between-group comparisons of the relative
change from baseline were performed with one-way analy-
ses of variance. Treatment differences for efﬁcacy variables
are presented as mean with 95% conﬁdence interval.Patient’s and physician’s global assessment of the clinical
efﬁcacy of aceclofenac and paracetamol at the end of the
trial was compared with the Cochran-Armitage trend test.
Primary efﬁcacy analyses were also adjusted for multiple
comparisons with the Hochberg step-up procedure41. All
tests of signiﬁcance were two-sided, and a P value< 0.05
was considered to be signiﬁcant. Statistical analyses were
performed using SAS (SAS Institute, Cary, NC).
Results
STUDY PATIENTS
A total of 169 patients were randomized in this study
(Fig. 1). After the exclusion of one patient, who never took
the study medication, valid data for efﬁcacy and safety
intention-to-treat analyses was available for 168 patients
(86 on paracetamol, 82 on aceclofenac). Demographic, dis-
ease characteristics, and clinical assessments at the start of
the trial were similar between both treatment groups (Tables
II and III). The only exception was a higher diastolic blood
pressure in the aceclofenac group (P¼ 0.031). About 75%
of all subjects were overweight (median BMI, 31 kg/m2
[interquartile range, 28 to 33 kg/m2]).
WITHDRAWAL FROM THE STUDY
More patients withdrew in the paracetamol group com-
pared with the aceclofenac group (17/86 [19.8%] vs 5/82
[6.1%], P¼ 0.011, for paracetamol vs aceclofenac, respec-
tively) (Fig. 1). The main reasons included lack of efﬁcacy
(n¼ 8 vs n¼ 1; P¼ 0.035, for paracetamol and aceclofe-
nac, respectively) and adverse events (n¼ 4 in each
group). Five patients, all in the paracetamol group, withdrew
for reasons unrelated to study medication (personal rea-
sons, n¼ 3; lost to follow-up, n¼ 1; and protocol violation,
n¼ 1).
COMPLIANCE
There was no difference between the two groups in the
number of tablets or sachets taken during the study. Pa-
tients took a mean [median; interquartile range] of 76%
[94%; 63e98] of the prescribed active sachets and 79%
[95% conﬁdence interval (CI); 85e98] of the placebo sa-
chets (P¼ 0.55), compared with 76% [95% CI; 64e99] of
the prescribed placebo tablets and 79% [95% CI; 75e99]
of the active tablets (P¼ 0.57).
EFFICACY
Primary efficacy variables
Changes in clinical efﬁcacy assessments at the end of
the trial are shown in Table III. After 6 weeks, patients
with symptomatic knee OA who received aceclofenac
(200 mg/day) had signiﬁcantly greater improvement than
patients treated with paracetamol (3000 mg/day) in all pri-
mary efﬁcacy measures (VAS, mean treatment difference,
7.64 mm [95% CI, 0.44e14.85 mm], P¼ 0.037), Lequesne
OA index (mean treatment difference, 1.41 [95% CI,
0.45e2.36], P¼ 0.004), and patient’s (mean treatment
difference, 0.33 [95% CI, 0.06e0.61], P¼ 0.017) and phys-
ician’s (mean treatment difference, 0.23 [95% CI,
0.01e0.47], P¼ 0.041) global assessments. These differ-
ences remained signiﬁcant (P< 0.05) after controlling for
multiple comparisons with the Hochberg step-up procedure.
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Patient’s characteristics at the start of the trial
Paracetamol, 3000 mg/day (n¼ 86) Aceclofenac, 200 mg/day (n¼ 82) P*
Age, year, meanSD 62.5 6.8 62.2 6.7 0.752
Female (%) 73 (85) 67 (82) 0.581y
Education level, year, meanSD 5.6 3.8 5.4 3.9 0.709
BMI, kg/m2, meanSD 30.5 3.8 30.9 3.7 0.457
Duration of OA, symptomatic, selected
knee, year, mean SD
8.5 6.5 8.4 6.4 0.914
ACR functional class (%)
I 32 (37.2) 31 (37.8)
II 34 (39.5) 24 (29.3) 0.466z
III 20 (23.3) 27 (32.9)
Radiological Classification, selected knee (%)
Grade II 29 (33.7) 35 (42.7)
Grade III 57 (66.3) 47 (57.3) 0.232y
Heart rate, bpm 76.7 15.0 75.4 14.7 0.598
Systolic blood pressure, mm Hg 147.2 21.1 150.5 21.6 0.321
Diastolic blood pressure, mm Hg 84.6 10.5 88.0 9.9 0.032
*Between-group comparisons were analyzed with unpaired t test.
yChi-square.
zManteleHaenszel test.Furthermore, although both treatment groups demonstrated
signiﬁcant clinical improvement from their baseline values
at end of trial, the percent improvement in patients treated
with aceclofenac was almost double that of patients treated
with paracetamol in pain (29% vs 17%), Lequesne OA in-
dex (21% vs 9%), patient’s global assessment (26% vs
13%) and physician’s global assessment (20% vs 13%).
At the end of the trial, both patient’s and physician’s global
assessments of the clinical efﬁcacy of the treatment were
generally more favourable for aceclofenac (P¼ 0.001)
(Table IV).
Secondary efficacy variables
Both treatment groups showed signiﬁcant improvement in
most secondary efﬁcacy endpoints, compared to their base-
line values (13/21 variables signiﬁcant for paracetamol vs
19/21 for aceclofenac). Patients treated with paracetamoldid not show any improvement in the duration of morning
stiffness, and the HAQ disability score (P> 0.05). Total
WOMAC (mean treatment difference, 4.28 [95% CI,
0.75e7.82], P¼ 0.018), WOMAC physical function (mean
treatment difference, 3.14 [95% CI, 0.66e5.61],
P¼ 0.013), full HAQ (mean treatment difference, 0.11
[95% CI, 0.01e0.22], P¼ 0.031), and lower extremities
HAQ (mean treatment difference, 0.15 [95% CI,
0.01e0.29], P¼ 0.037) showed mean treatment effects in
favour of aceclofenac. None of the remaining secondary ef-
ﬁcacy variables, including the eight domains of the SF-36
questionnaire, were signiﬁcantly different between the ace-
clofenac and paracetamol treatment groups.
SAFETY AND TOLERABILITY
Both paracetamol and aceclofenac were well tolerated,
and the incidence of patients reporting adverse eventsTable III
Intention-to-treat analysis for primary efficacy measures at baseline, changes at 6 weeks, and treatment effect for all study patients, by
treatment group (meanSD)
Baseline* Change at 6 weeks
(within-group comparisons)
Treatment difference
(between-group comparisons)y
Paracetamol,
3000 mg/day
(n¼ 86)
Aceclofenac,
200 mg/day
(n¼ 82)
Paracetamol,
3000 mg/day
(n¼ 86)
Aceclofenac,
200 mg/day
(n¼ 82)
Mean (95% CI) P
Pain, VAS, 0e100 62.40 16.97 62.19 20.09 10.70 22.31z 18.34 24.86z 7.64 (0.44, 14.85) 0.037
Lequesne
index, 0e24
11.11 3.24 11.15 3.75 0.97 3.11x 2.37 3.14z 1.41 (0.45, 2.36) 0.004
Patient global
assessment,
Likert scale, 1e5
2.48 0.66 2.55 0.77 0.33 0.85z 0.66 0.95z 0.33 (0.06, 0.61) 0.017
Physician global
assessment,
Likert scale, 1e5
3.17 0.62 3.23 0.81 0.40 0.69z 0.63 0.81z 0.23 (0.01, 0.47) 0.041
*At baseline all between-group differences were not signiﬁcant at P¼ 0.05; unpaired t test.
yPositive changes favour aceclofenac, P values from ANOVA.
zP< 0.001 vs baseline.
xP< 0.01 vs baseline.
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the 86 patients taking paracetamol and 26 (32%) of the
82 patients receiving aceclofenac experienced at least
one adverse event (P¼ 0.71). However, patients on aceclo-
fenac reported a higher total number of adverse events than
patients on paracetamol (41 vs 33), and most of them were
of mild or moderate intensity. Sixty-one (71%) patients tak-
ing paracetamol had no adverse events, eighteen (21%)
had one adverse event, six (7%) had two, and one (1%)
had three adverse events. In contrast, 56 (68%) patients
taking aceclofenac had no adverse events, 15 (18%) pa-
tients had one adverse event, eight (10%) had two, two
(2%) had three, and ﬁnally one (1%) had four (P¼ 0.329).
The majority of the adverse events reported were related
with GI origin, and patients on aceclofenac had a signiﬁ-
cantly higher percentage of adverse events classiﬁed by
their physicians as related or possibly related to the study
medication than did patients on paracetamol (61.0% vs
35.5%; P¼ 0.032, for aceclofenac and paracetamol,
respectively).
GI adverse events were the most frequently reported
events. About one third (12/33) of adverse events on pa-
tients receiving paracetamol and half (22/41) on patients
Fig. 1. Flow chart of patients through the trial.receiving aceclofenac were GI related (Table V). Broken
down by treatment group (paracetamol/aceclofenac), the
speciﬁc GI adverse events were: pyrosis (2/7), epigastric
pain (3/5), abdominal pain (2/2), ﬂatulence or meteorism
(0/4), diarrhoea (2/e), and others (3/4).
Almost all reported adverse events were described as
mild or moderate in severity. Twenty ﬁve patients on para-
cetamol reported 33 adverse events, 26 mild, and seven
moderate; compared with 26 patients on aceclofenac who
reported 40 adverse events, 29 mild and 11 moderate
(P¼ 0.53). One patient on aceclofenac group was admitted
into hospital due to an accidental injury not treatment
related. No other serious adverse event requiring hospitali-
zation or life-threatening was seen during the trial. Never-
theless, four patients in each treatment group were
withdrawn owing to an adverse event. Among the patients
treated with paracetamol, adverse events that led to early
discontinuation were as follows: rash (n¼ 1), dizziness
(n¼ 1), increased gamma glutamyl transferase (n¼ 1),
and epigastralgia associated with myalgia (n¼ 1). Among
the patients who received aceclofenac, adverse events
that led to withdrawal were as follows: epigastric pain
(n¼ 2), abdominal distension with meteorism (n¼ 1), and
an allergic reaction with urticaria (n¼ 1).
Discussion
This study shows that patients with symptomatic OA of
the knee treated for a period of six weeks with aceclofenac,
200 mg/day, had a signiﬁcantly greater improvement than
patients treated with paracetamol, 3000 mg/day, for four pri-
mary endpoints covering pain, function and overall assess-
ment. There were also signiﬁcant improvements in favour of
aceclofenac on several health-related quality of life mea-
sures, including WOMAC functional capacity (P¼ 0.013),
total WOMAC score (P¼ 0.018), full HAQ (P¼ 0.031),
and lower-extremity HAQ (P¼ 0.037). These results are
consistent with the ﬁndings of three recently published trials
indicating superior efﬁcacy of NSAIDs (rofecoxib, 25 mg/
day16, celecoxib, 200 mg/day7; and diclofenac 150 mg/dayþ
misoprotol 400 mg/day15), compared with paracetamol
4000 mg/day.
Moreover, although both groups realized signiﬁcant im-
provements compared with their baseline values, the per-
cent improvement in the four primary efﬁcacy variables for
patients treated with aceclofenac was greater than with par-
acetamol, in some cases twice as large (e.g., patients’
global assessment, 26% vs 13%; Lequesne OA index,
21% vs 9%). In addition, more patients in the paracetamolTable IV
Patient’s and physician’s global assessment of the clinical efficacy of the treatment at the end of the trial (%)
Patient* Physician*
Paracetamol, 3000 mg/day
(n¼ 86)
Aceclofenac, 200 mg/day
(n¼ 82)
Paracetamol, 3000 mg/day
(n¼ 86)
Aceclofenac, 200 mg/day
(n¼ 82)
A lot better 2 (2.3) 12 (14.6) 2 (2.3) 14 (17.1)
Fairly better 16 (18.6) 29 (35.4) 18 (20.9) 24 (29.3)
Little better 33 (38.4) 23 (28.0) 31 (36.0) 26 (31.7)
Same 16 (18.6) 10 (12.2) 23 (26.7) 12 (14.6)
Little worse 9 (10.5) 2 (2.4) 5 (5.8) 2 (2.4)
Fairly worst 8 (9.3) 3 (3.7) 5 (5.8) 2 (2.4)
A lot worst 1 (1.2) 1 (1.2) 1 (1.2) e
Not available 1 (1.2) 2 (2.4) 1 (1.2) 2 (2.4)
*Cochran e Armitage trend test, both patient and physician, P¼ 0.001, for paracetamol vs aceclofenac.
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pared with those receiving aceclofenac (eight vs one pa-
tient, P¼ 0.035), with no difference in the number of
patients who discontinued the trial due to adverse events.
Although the absolute magnitude of the observed treat-
ment differences in this study were small, the degree of im-
provement in each of the four primary endpoints was
between 9% and 17% for patients treated with paracetamol,
and between 20% and 29% for patients receiving aceclofe-
nac. This degree of improvement is consistent with ranges
reported in other clinical trials assessing NSAID for OA of
the knee, which often do not exceed 30%2. The improve-
ments in functional capacity with aceclofenac, when as-
sessed by both the HAQ and the WOMAC questionnaires,
was also consistent with other studies reporting improve-
ment in function among patients receiving NSAIDs11,15,16,36.
The patient preference for aceclofenac vs paracetamol was
also in agreement with previous reports15,42,43, probably due
to a greater satisfaction with the degree of symptomatic relief
associated with NSAIDs.
The good safety proﬁle of aceclofenac was consistent with
that reported in other studies42e45. A caseecontrol study of
patients with a primary diagnosis of upper GI bleeding admit-
ted to 10 hospitals in Spain and eight hospitals in Italy, rep-
resented 10,734,897 person-years of experience found
that the odds ratio of GI bleeding associated with aceclofe-
nac exposure was 1.4% (95% CI 0.6, 3.3), compared to con-
trol subjects matched according to age, sex, and centre46.
Similarly, good results for tolerability were reported in a longi-
tudinal study of patients presenting with haematemesis, me-
lena, or both, in conjunction with an endoscopic diagnosis of
upper GI bleeding, and admitted to two Spanish hospitals47.
Aceclofenac had the lowest incidence rate of upper GI bleed-
ing among 13 NSAIDs evaluated (1.7 incidents per 1000
Table V
Frequency of adverse events for patients with at least one
treatment dose*
Paracetamol,
3000 mg/day
(n¼ 86)
Aceclofenac,
200 mg/day
(n¼ 82)
P
Mild /moderate Mild /moderate
Gastrointestinal 12/0 (1)y 18/4 (3)
Musculoskeletal pain,
myalgias
4/1 6/2
Hypertension 2/0 2/0
Infection 2/1 1/0
Psychiatric 3/0 0/1
Injury, accidental 0/1 0/2;1z
Dizziness 1/2 (1) e
Allergic reaction 0/1 (1) 0/1 (1)
Headache 0/1 1/0
Peripheral edema e 0/1
Elevated GGTx 1/0 (1) e
Hypercholesterolemia e 1/0
Conjuntival
hemorrhage
1/0 e
Total adverse events 33;26/7 41;29/11 0.53
Number of patients 25 26 0.71
P values from chi square.
*Some patients had more than one adverse event.
yValues in parentheses indicate number of patients who with-
drew due to that adverse event.
zOne patient admitted to hospital due to an accidental injury was
considered severe.
xGGT: gamma glutamyl transferase.person-years treatment). This was in contrast to the highest
reported rate of 25.8 incidents per 1000 person-years treat-
ment for ketorolac47. Concerns about the cardiovascular ef-
fects of the new COX-2 speciﬁc NSAIDs have raised
uncertainties about the cardiovascular risk related with
more classical NSAIDS, as aceclofenac/diclofenac. This is
a short trial, not aimed to detect differences in cardiovascular
morbidity/mortality. More studies are needed to weigh the
potential cardiovascular and GI risks/beneﬁts of the less
COX-2 selective NSAIDS such as aceclofenac.
In this study, unlike previously published trials, the dose
of paracetamol used (3000 mg/day) was less than the
maximum recommended dose (4000 mg/day). During the
planning stages for this trial, European League Against
Rheumatism recommendations48 for the management of
OA of the knee had not yet been published and we decided
to use the lower (3000 mg/day) recommended dose pro-
posed by the ACR to represent more accurately the situa-
tion in daily clinical practice. Although it is possible that
a maximum dose of paracetamol (4000 mg/day) could
have improved the response in the paracetamol group, re-
sults of two large published trials do not support this argu-
ment15,16. Furthermore, recent reports have suggested an
increase of serious GI complications when using paraceta-
mol >2000 mg/day49,50, although these observations have
been questioned51.
There are some issues related to generalizability of the re-
sults of this study. Patients were selected from a population
with OA of the knee attended by rheumatologists, and thus
may differ from patients who consult primary care physicians.
It has been suggested that NSAIDsmay bemore effective for
patients with more severe disease15. It would also be inap-
propriate to generalize the results of this trial for periods lon-
ger than 6 weeks. However, for purposes of comparison, it
should be noted that most data discussed above are from tri-
als with a duration of between 2 and 12 weeks.
In conclusion, our results provide some additional informa-
tion to the relatively few data existing comparingNSAIDswith
paracetamol in the management of OA. In this 6-week study
aceclofenac was superior to paracetamol in pain reduction
and functional improvement in symptomatic patients with
OA of the knee, with no signiﬁcant difference in tolerability.
Our ﬁndings give additional support to the notion thatNSAIDs
may bemore effective than simple analgesics in OA patients,
especially when used at short term.
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